Clinical trials
High Risk Prostate Cancer clinical trials
Below are recruiting high risk prostate cancer clinical trials, each written for real people, not researchers. We’re tracking 341 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07042438RecruitingPhase 2
Fecal transplant to improve CAR T therapy for lymphoma
This study tests whether a fecal transplant (transferring healthy gut bacteria) can improve outcomes for people with certain lymphomas who have taken strong antibiotics and are about to get CAR T-cell therapy (Yescarta). The goal is to see if rebuilding gut bacteria helps the treatment work better.
Duarte, CaliforniaAges 18 years+ - NCT06387017Recruiting
Can blood tests improve lung cancer screening in smokers with artery disease?
This study looks at whether certain blood tests can help find lung cancer early in people who have smoked for a long time and also have artery disease. The goal is to see if adding these tests to current screening methods can better identify those at highest risk.
MarseilleAges 45–80 - NCT06835049RecruitingPhase 2
Heating therapy before surgery for high-risk soft tissue sarcoma
This trial tests a new approach for high-risk soft tissue sarcoma of the arm, leg, or trunk. Before surgery, you would receive chemotherapy combined with local hyperthermia (a treatment that gently heats the tumor area) to see if this can improve outcomes.
AarauAges 18 years+ - NCT07591649RecruitingPhase 1/Phase 2
NK cells for high-risk blood cancers before transplant
This study tests a new type of immune cell therapy (called AdaptNK cells) for patients with high-risk myeloid diseases (blood cancers affecting bone marrow cells) who are preparing for a stem cell transplant. The goal is to help control the cancer and prepare your body for the transplant.
Minneapolis, MinnesotaAges 18 years+ - NCT04269902RecruitingPhase 3
Early treatment check for high-risk CLL/SLL
This Phase 3 trial studies an early treatment approach for people with high-risk CLL or SLL who have not yet needed standard therapy. It aims to see if treating earlier can improve outcomes while keeping side effects manageable.
Birmingham, AlabamaAges 18 years+ - NCT03920033Recruiting
Radiation schedule for prostate cancer PSA relapse after surgery
This trial compares two different radiation schedules to treat prostate cancer that returned based on rising PSA blood tests after prostatectomy (prostate removal). If you qualify, it may help you and your team choose a radiation approach with the goal of controlling PSA relapse.
SeoulAges 20 years+ - NCT05768464RecruitingPhase 2
Surgery aftercare for non-clear kidney cancer at high risk
This Phase 2 trial studies an after-surgery treatment for people with non-clear types of kidney cancer who are at high risk of coming back. It aims to lower the chance of recurrence by giving extra therapy after your tumor is completely removed.
Nanjing, JiangsuAges 18–75 - NCT05943379RecruitingPhase 2
RC48 antibody plus gemcitabine for high-risk bladder cancer
This Phase 2 study tests RC48, an antibody-based drug, combined with gemcitabine to treat high-risk, non-muscle invasive bladder cancer that has not responded well to BCG or cannot receive BCG. It may help shrink tumors and reduce the chance of the cancer coming back.
Beijing, Beijing MunicipalityAges 18 years+ - NCT05956639RecruitingPhase 3
Rezvilutamide with ADT and chemo: shorter versus longer treatment
This Phase 3 trial compares two lengths of rezvilutamide treatment when given with hormone therapy (ADT) and chemotherapy for men with advanced prostate cancer. It aims to find which treatment duration works best and is safest to help control the cancer.
Nanjing, JiangsuAges 18 years+ - NCT06092957RecruitingPhase 3
Reduced radiation after chemo-immunotherapy for high-risk nasopharyngeal cancer
This trial tests whether a lower dose of radiation, with or without additional chemo-immunotherapy, works as well as the standard full-dose chemoradiation for people with advanced nasopharyngeal cancer who had a complete response after initial chemo-immunotherapy.
Guangzhou, GuangdongAges 18–70 - NCT06330909Recruiting
Focused radiation boost for prostate cancer
This trial tests a newer, more precise radiation treatment that gives a higher dose to the main tumor while keeping radiation to the rest of the prostate the same. It is for men with intermediate- or high-risk prostate cancer who haven't had prior prostate radiation or removal.
Freiburg im Breisgau, Baden-WurttembergAges 18 years+ - NCT06449664Recruiting
Exercise program for men on hormone therapy for prostate cancer
This study tests whether a supervised exercise program can help men with prostate cancer stay stronger and feel better during combined radiation and hormone therapy. You may be able to join if you are about to start these treatments and are otherwise healthy enough to exercise.
StockholmAges 50–80 - NCT06407947RecruitingEarly Phase 1
CT071 for high-risk newly diagnosed multiple myeloma
This trial tests an experimental therapy called CT071 for people with newly diagnosed, high-risk multiple myeloma. It aims to see if this treatment can help control the disease in people who have certain aggressive features.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT06482684RecruitingPhase 2
CAR-T cell therapy for new, high-risk mantle cell lymphoma
This study tests a type of immunotherapy called CAR-T cells (modified immune cells) for people with untreated, high-risk mantle cell lymphoma. It aims to see if this therapy can help control the disease early on.
MainzAges 18–75 - NCT06521710Recruiting
Nerve grafting to preserve erections after prostate removal
This trial tests if a nerve grafting technique can help preserve erectile function after robotic surgery for high-risk localized prostate cancer. It may be an option for men with good preoperative erectile function.
Montreal, QuebecAges 18 years+ - NCT07552922Recruiting
Understanding men's preferences about breast changes from prostate cancer treatment
This study helps doctors understand what men with prostate cancer worry about regarding breast changes from hormone therapy. Your input will help shape future treatment strategies to reduce or prevent these side effects.
Sydney, New South WalesAges 18 years+ - NCT06640959Recruiting
Bowel health study for prostate cancer radiation
This study tests whether a daily drink can help reduce bowel side effects caused by radiation for prostate cancer. If you are about to start radiation for intermediate to high-risk prostate cancer, you may be able to join.
Manchester, Greater ManchesterAges 18 years+ - NCT06398613Recruiting
Using PSMA PET scan before prostate cancer surgery
This trial is testing whether a special scan (PSMA PET/CT) before surgery can help doctors decide if you need to remove lymph nodes. It is for men with high-risk prostate cancer who are already planning to have robot-assisted prostate removal.
OsloAges 18 years+ - NCT07334275Recruiting
Detecting leftover cancer cells after prostate removal
This trial tests a new way to find microscopic cancer cells (minimal residual disease) in the blood after prostate surgery. If successful, it could help doctors decide if additional treatment is needed.
NijmegenAges 18 years+ - NCT07259213RecruitingPhase 1/Phase 2
Study of a new drug (161Tb-RAD402) for men with advanced prostate cancer
This trial tests a new radioactive drug designed to target and destroy prostate cancer cells. It is for men whose cancer has continued to grow despite hormone therapy and other treatments like enzalutamide or abiraterone.
Wollongong, New South WalesAges 18 years+ - NCT07162779Enrolling by invitation
New PET scan for advanced prostate cancer patients
This trial tests a new type of PET scan using a radioactive tracer called [68Ga]DOTA-IR-780-C-4 to see if it can find prostate cancer cells that express a protein called PSMA. If you have advanced prostate cancer that has stopped responding to standard treatments, this scan may help your doctor better understand your cancer and possibly guide future care.
Wuxi, JiangsuAges 18–80 - NCT07093866RecruitingPhase 2
Targeted drug combo for advanced prostate cancer
This trial tests a combination of two drugs—disitamab vedotin (a targeted antibody-drug that attacks HER2-positive cancer cells) and abiraterone (a hormone therapy)—to see if they can slow or shrink prostate cancer that has spread and become resistant to standard treatments.
Nanjing, JiangsuAges 18–75 - NCT06977711RecruitingPhase 1
Testing a new drug combo for high-risk DLBCL
This trial is testing a new combination of drugs for people with a high-risk type of lymphoma called DLBCL who have not been treated before. It adds loncastuximab and roflumilast to the standard R-CHOP therapy to see if it works better at fighting the cancer.
San Antonio, TexasAges 18 years+ - NCT06932757RecruitingPhase 2
Quisinostat after treatment for high-risk uveal melanoma
This trial tests whether taking quisinostat pills after standard treatment can lower the chance of uveal melanoma coming back in people whose original tumor had high-risk features. It is for patients who have finished their eye treatment (surgery or radiation) within the past 6 months and have no signs that the cancer has spread.
Miami, FloridaAges 19 years+
Hear when a new High Risk Prostate Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for high risk prostate cancer?
- Yes. Clin2 currently lists 341 recruiting high risk prostate cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a high risk prostate cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a high risk prostate cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.